Skip to main content
CI
NYSE Finance

Cigna 10-Q Details Q3 GAAP EPS of $5.47 and $73.7B Revenue Behind Raised Guidance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Financial
Sentiment info
Neutral
Importance info
7
Price
$312.17
Mkt Cap
$82.488B
52W Low
$255.528
52W High
$318.05
52W Position info
22% above low
Off High info
1.8% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

CI sits 22% above its 52-week low of $255.528.

Summary

Cigna's Q3 10-Q confirms $73.7 billion of revenue and $7.98 of adjusted EPS, but shows GAAP net income down 23% and Evernorth margin pressure offset by stronger Cigna Healthcare results.


Key Events · Earnings and Guidance · CI

  • Q3 Revenue Grows 6% to $73.7B

    Total revenues rose to $73,683 million from $69,748 million, led by pharmacy revenues of $58,982 million (+5%) and premiums of $9,885 million (+9%).

  • GAAP Net Income Falls 23%

    Shareholders' net income was $1,442 million versus $1,868 million, reflecting the absence of last year's $38 million pre-tax HCSC sale gain and lower net investment performance; diluted EPS fell to $5.47 from $6.98.

  • Adjusted EPS Rises to $7.98

    Adjusted income from operations was $2,104 million versus $2,096 million, with nine-month adjusted EPS of $23.55 versus $21.76.

  • Evernorth Margin Pressure, Cigna Healthcare Strong

    Evernorth pre-tax adjusted income fell 4% to $1,829 million on client-focused initiatives, while Cigna Healthcare rose 15% to $1,193 million with a medical care ratio of 85.0%.


Analysis · CI · Finance

The headline numbers were already out this morning via the 8-K and wire reports, so the 10-Q's news value is in the detail: GAAP shareholders' net income fell 23% to $1,442 million on the absence of last year's HCSC sale gain, while adjusted income from operations held flat at $2,104 million and adjusted EPS rose to $7.98 from $7.83. Evernorth's pre-tax adjusted income slipped 4% to $1,829 million as client-focused initiatives and the rebate-free model transition bit into pharmacy benefit margins, offset by Cigna Healthcare's 15% jump to $1,193 million on a 9% revenue increase. Capital return has slowed sharply — 1.8 million shares repurchased for about $500 million versus 8.2 million for $2.6 billion a year ago — leaving $6.23 billion of authorization unused while debt-to-capitalization improved to 41.8%.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CI was trading at $312.17 on NYSE in the Finance sector, with a market capitalization of approximately $82.5B. The 52-week trading range was $255.53 to $318.05. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CI - Latest Insights

CI
Nov 05, 2026, 1:00 PM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $302.34
Real-time Price: $271.65 info
Change: -$30.69 (-10%) info
Market Cap: $71.947B info
CI
Nov 05, 2026, 6:51 AM EST
Source: dpa-AFX
Importance Score:
7
Price at Filing: $307.26
Real-time Price: $271.65 info
Change: -$35.61 (-12%) info
Market Cap: $71.947B info
CI
Nov 05, 2026, 6:15 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $307.26
Real-time Price: $271.65 info
Change: -$35.61 (-12%) info
Market Cap: $71.947B info
CI
Nov 05, 2026, 6:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $300.90
Real-time Price: $271.65 info
Change: -$29.25 (-10%) info
Market Cap: $71.947B info
CI
Oct 01, 2026, 3:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $271.83
Real-time Price: $271.65 info
Change: -$0.1825 (-0.07%) info
Market Cap: $71.947B info